The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization

Journal of Allergy and Clinical Immunology

Volumn 136, Issue 5, 2015, Pages 1254-1264

  Noda, Shinji ^a   Suárez Fariñas, Mayte ^a,b   Ungar, Benjamin ^a,b   Kim, Soo Jung ^b   De Guzman Strong, Cristina ^c   Xu, Hui ^b   Peng, Xiangyu ^b   Estrada, Yeriel D ^b   Nakajima, Saeko ^d   Honda, Tetsuya ^d   Shin, Jung U ^e   Lee, Hemin ^e   Krueger, James G ^a   Lee, Kwang Hoon ^e   Kabashima, Kenji ^d   Guttman Yassky, Emma ^a,b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e Yonsei University College of Medicine   (South Korea)

Author keywords

acanthosis; Asian; Atopic dermatitis; European American; parakeratosis; psoriasis; TH1; TH17; TH2; TH22

Indexed keywords

CALGRANULIN C; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GAMMA INTERFERON RECEPTOR 1; IMMUNOGLOBULIN E; INTERLEUKIN 17; INTERLEUKIN 19; INTERLEUKIN 22; KI 67 ANTIGEN; CYTOKINE;

ACANTHOSIS; ADULT; AGED; ARTICLE; ASIAN; ATOPIC DERMATITIS; COMPARATIVE STUDY; CONTROLLED STUDY; DENDRITIC CELL; DISEASE ACTIVITY; DISEASE SEVERITY; EPIDERMIS; EPIDERMIS HYPERPLASIA; EUROPEAN AMERICAN; FEMALE; GENE CLUSTER; GENE INDUCTION; GENOMICS; HUMAN; HUMAN CELL; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; PARAKERATOSIS; POLARIZATION; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PSORIASIS; REAL TIME POLYMERASE CHAIN REACTION; SKIN BIOPSY; SKIN DEFECT; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TH2 CELL; TH22 CELL; ADOLESCENT; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CAUCASIAN; CELL DIFFERENTIATION; DISEASE COURSE; ETHNOLOGY; GENE EXPRESSION PROFILING; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PHENOTYPE; SKIN; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CELL DIFFERENTIATION; CYTOKINES; DERMATITIS, ATOPIC; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; PSORIASIS; SKIN; TH17 CELLS; TH2 CELLS; YOUNG ADULT;

EID: 84956603674     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2015.08.015     Document Type: Article

References (80)

1. Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol 2014;134: 769-79.
2. Hanifin JM, Reed ML. Eczema Prevalence and Impact Working Group. A population-based survey of eczema prevalence in the United States. Dermatitis 2007;18:82-91.
3. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol 2014;70:338-51.
4. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol 2013;132:1132-8.
5. Margolis JS, Abuabara K, Bilker W, Hoffstad O, Margolis DJ. Persistence of mild to moderate atopic dermatitis. JAMA Dermatol 2014;150:593-600.
6. Flohr C, Mann J. New insights into the epidemiology of childhood atopic dermatitis. Allergy 2014;69:3-16.
7. Tokura Y. Extrinsic and intrinsic types of atopic dermatitis. J Dermatol Sci 2010; 58:1-7.
8. Noda S, Krueger JG, Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol 2015;135:324-36.
9. Gittler JK, Shemer A, Suárez-Fariñas M, Fuentes-Duculan J, Gulewicz KJ, Wang CQ, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol 2012;130:1344-54.
10. Suárez-Fariñas M, Dhingra N, Gittler J, Shemer A, Cardinale I, de Guzman Strong C, et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol 2013;132:361-70.
11. Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, Zaba LC, Cardinale I, Nograles KE, et al. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol 2008;181:7420-7.
12. Guttman-Yassky E, Suárez-Fariñas M, Chiricozzi A, Nograles KE, Shemer A, Fuentes-Duculan J, et al. Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. J Allergy Clin Immunol 2009; 124:1235-44.e58.
13. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366:1190-9.
14. Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012;366:1181-9.
15. Sofen H, Smith S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol 2014;133:1032-40.
16. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med 2014; 371:326-38.
17. Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014;371:130-9.
18. Hamilton JD, Suárez-Fariñas M, Dhingra N, Cardinale I, Li X, Kostic A, et al. Dupilumab improves the molecular signature in skin of patients with moderateto-severe atopic dermatitis. J Allergy Clin Immunol 2014;134:1293-300.
19. Torrelo A. Atopic dermatitis in different skin types. What is to know? J Eur Acad Dermatol Venereol 2014;28(suppl 3):2-4.
20. Saeki H, Tsunemi Y, Fujita H, Kagami S, Sasaki K, Ohmatsu H, et al. Prevalence of atopic dermatitis determined by clinical examination in Japanese adults. J Dermatol 2006;33:817-9.
21. Sugiura H, Umemoto N, Deguchi H, Murata Y, Tanaka K, Sawai T, et al. Prevalence of childhood and adolescent atopic dermatitis in a Japanese population: comparison with the disease frequency examined 20 years ago. Acta Derm Venereol 1998;78:293-4.
22. Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol 2008;128:2625-30.
23. Czarnowicki T, Gonzalez J, Shemer A, Malajian D, Xu H, Zheng X, et al. Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. J Allergy Clin Immunol 2015;136:104-15.e7.
24. Tintle S, Shemer A, Suárez-Fariñas M, Fujita H, Gilleaudeau P, Sullivan-Whalen M, et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J Allergy Clin Immunol 2011;128:583-93, e1-4.
25. Khattri S, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Finney R, et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. J Allergy Clin Immunol 2014;133: 1626-34.
26. Johnson-Huang LM, Suarez-Farinas M, Sullivan-Whalen M, Gilleaudeau P, Krueger JG, Lowes MA. Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. J Invest Dermatol 2010;130:2654-63.
27. Jolliffe IT. Principal component analysis. New York: Springer-Verlag; 1986.
28. Stacklies W, Redestig H, Scholz M, Walther D, Selbig J. pcaMethods-A bioconductor package providing PCA methods for incomplete data. Bioinformatics 2007;23:1164-7.
29. Scholz M, Kaplan F, Guy CL, Kopka J, Selbig J. Non-linear PCA: a missing data approach. Bioinformatics 2005;21:3887-95.
30. Papp KA, Reid C, Foley P, Sinclair R, Salinger DH, Williams G, et al. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. J Invest Dermatol 2012;132:2466-9.
31. Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, Whynot J, Novitskaya I, Cardinale I, et al. Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. J Allergy Clin Immunol 2007;119: 1210-7.
32. Kim BE, Leung DY, Boguniewicz M, Howell MD. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol 2008;126:332-7.
33. Esaki H, Ewald DA, Ungar B, Rozenblit M, Zheng X, Xu H, et al. Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection. J Allergy Clin Immunol 2015;135:153-63.
34. Suárez-Fariñas M, Ungar B, Correa da Rosa J, Ewald DA, Rozenblit M, Xu H, et al. RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications. J Allergy Clin Immunol 2015;135:1218-27.
35. Bhattacharya T, Silverberg JI. Efficacy of systemic treatments for atopic dermatitis in racial and ethnic minorities in the United States. JAMA Dermatol 2014; 150:1232-4.
36. Bin L, Edwards MG, Heiser R, Streib JE, Richers B, Hall CF, et al. Identification of novel gene signatures in patients with atopic dermatitis complicated by eczema herpeticum. J Allergy Clin Immunol 2014;134:848-55.
37. Heratizadeh A, Wichmann K, Werfel T. Food allergy and atopic dermatitis: how are they connected? Curr Allergy Asthma Rep 2011;11:284-91.
38. McLean WH, Palmer CN, Henderson J, Kabesch M, Weidinger S, Irvine AD. Filaggrin variants confer susceptibility to asthma. J Allergy Clin Immunol 2008; 121:1294-5, author reply 1295-6.
39. Brown SJ, McLean WH. One remarkable molecule: filaggrin. J Invest Dermatol 2012;132:751-62.
40. Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med 2011;365:1315-27.
41. Czarnowicki T, Gonzalez J, Malajian D, Shemer A, Noda S, Talasila S, et al. Early pediatric atopic dermatitis shows only a CLA1 Th2/Th1 imbalance, while adults acquire CLA1 Th22/Tc22 subsets. J Allergy Clin Immunol 2015 [Epub ahead of print].
42. Moore MM, Rifas-Shiman SL, Rich-Edwards JW, Kleinman KP, Camargo CA, Gold DR, et al. Perinatal predictors of atopic dermatitis occurring in the first six months of life. Pediatrics 2004;113:468-74.
43. Suárez-Fariñas M, Tintle SJ, Shemer A, Chiricozzi A, Nograles K, Cardinale I, et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol 2011;127:954-64, e1-4.
44. Alsaad KO, Ghazarian D. My approach to superficial inflammatory dermatoses. J Clin Pathol 2005;58:1233-41.
45. Yoshida K, Kubo A, Fujita H, Yokouchi M, Ishii K, Kawasaki H, et al. Distinct behavior of human Langerhans cells and inflammatory dendritic epidermal cells at tight junctions in patients with atopic dermatitis. J Allergy Clin Immunol 2014; 134:856-64.
46. Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis-part II: immune cell subsets and therapeutic concepts. J Allergy Clin Immunol 2011;127:1420-32.
47. Hao JQ. Targeting interleukin-22 in psoriasis. Inflammation 2014;37:94-9.
48. Sabat R, Ouyang W, Wolk K. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov 2014;13:21-38.
49. Sa SM, Valdez PA, Wu J, Jung K, Zhong F, Hall L, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 2007;178:2229-40.
50. Witte E, Kokolakis G, Witte K, Philipp S, Doecke WD, Babel N, et al. IL-19 is a component of the pathogenetic IL-23/IL-17 cascade in psoriasis. J Invest Dermatol 2014;134:2757-67.
51. Huang F, Wachi S, Thai P, Loukoianov A, Tan KH, Forteza RM, et al. Potentiation of IL-19 expression in airway epithelia by IL-17A and IL-4/IL-13: important implications in asthma. J Allergy Clin Immunol 2008;121:1415-21, e1-3.
52. Danso MO, van Drongelen V, Mulder A, van Esch J, Scott H, van Smeden J, et al. TNF-A and Th2 cytokines induce atopic dermatitis-like features on epidermal differentiation proteins and stratum corneum lipids in human skin equivalents. J Invest Dermatol 2014;134:1941-50.
53. Mills KH. Induction, function and regulation of IL-17-producing T cells. Eur J Immunol 2008;38:2636-49.
54. Paust HJ, Turner JE, Riedel JH, Disteldorf E, Peters A, Schmidt T, et al. Chemokines play a critical role in the cross-regulation of Th1 and Th17 immune responses in murine crescentic glomerulonephritis. Kidney Int 2012;82:72-83.
55. Damsker JM, Hansen AM, Caspi RR. Th1 and Th17 cells: adversaries and collaborators. Ann N Y Acad Sci 2010;1183:211-21.
56. Noster R, Riedel R, Mashreghi MF, Radbruch H, Harms L, Haftmann C, et al. IL-17 and GM-CSF expression are antagonistically regulated by human T helper cells. Sci Transl Med 2014;6:241ra80.
57. Zhang N, Van Zele T, Perez-Novo C, Van Bruaene N, Holtappels G, DeRuyck N, et al. Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease. J Allergy Clin Immunol 2008;122:961-8.
58. Jiang XD, Li GY, Li L, Dong Z, Zhu DD. The characterization of IL-17A expression in patients with chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy 2011;25:e171-5.
59. Bachert C, Zhang N. Chronic rhinosinusitis and asthma: novel understanding of the role of IgE above atopy. J Intern Med 2012;272:133-43.
60. Malajian D, Guttman-Yassky E. New pathogenic and therapeutic paradigms in atopic dermatitis. Cytokine 2015;73:311-8.
61. Dunbar GC, Kuchibhatla RV, Lee G, Group T-ACS. A randomized double-blind study comparing 25 and 50 mg TC-1734 (AZD3480) with placebo, in older subjects with age-associated memory impairment. J Psychopharmacol 2011;25: 1020-9.
62. Lee JS, Lee WW, Kim SH, Kang Y, Lee N, Shin MS, et al. Age-associated alteration in naive and memory Th17 cell response in humans. Clin Immunol 2011; 140:84-91.
63. Samorano LP, Hanifin JM, Simpson EL, Leshem YA. Inadequate response to ustekinumab in atopic dermatitis-A report of two patients. J Eur Acad Dermatol Venereol 2014 [Epub ahead of print].
64. Fernández-Antón Martinez MC, Alfageme Roldán F, Ciudad Blanco C, Suárez Fernández R. Ustekinumab in the treatment of severe atopic dermatitis: a preliminary report of our experience with 4 patients. Actas Dermosifiliogr 2014;105: 312-3.
65. Agusti-Mejias A, Messeguer F, Garcia R, Febrer I. Severe refractory atopic dermatitis in an adolescent patient successfully treated with ustekinumab. Ann Dermatol 2013;25:368-70.
66. Puya R, Alvarez-López M, Velez A, Casas Asuncion E, Moreno JC. Treatment of severe refractory adult atopic dermatitis with ustekinumab. Int J Dermatol 2012; 51:115-6.
67. Nast A, Jacobs A, Rosumeck S, Werner RN. Efficacy and safety of systemic longterm treatments for moderate-to-severe psoriasis-A systematic review and metaanalysis. J Invest Dermatol 2015 [Epub ahead of print].
68. Gordon KB, Leonardi CL, Lebwohl M, Blauvelt A, Cameron GS, Braun D, et al. A 52-week, open-label study of the efficacy and safety of ixekizumab, an antiinterleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol 2014;71:1176-82.
69. Eyerich S, Onken AT, Weidinger S, Franke A, Nasorri F, Pennino D, et al. Mutual antagonism of T cells causing psoriasis and atopic eczema. N Engl J Med 2011; 365:231-8.
70. Quaranta M, Knapp B, Garzorz N, Mattii M, Pullabhatla V, Pennino D, et al. Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and eczema. Sci Transl Med 2014;6:244ra90.
71. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361:496-509.
72. Bieber T. Atopic dermatitis. N Engl J Med 2008;358:1483-94.
73. Kubota K, Kamijima Y, Sato T, Ooba N, Koide D, Iizuka H, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open 2015;5:e006450.
74. Kim KW, Myers RA, Lee JH, Igartua C, Lee KE, Kim YH, et al. Genome-wide association study of recalcitrant atopic dermatitis in Korean children. J Allergy Clin Immunol 2015 [Epub ahead of print].
75. Esparza-Gordillo J, Weidinger S, Fölster-Holst R, Bauerfeind A, Ruschendorf F, Patone G, et al. A common variant on chromosome 11q13 is associated with atopic dermatitis. Nat Genet 2009;41:596-601.
76. Sun LD, Xiao FL, Li Y, Zhou WM, Tang HY, Tang XF, et al. Genome-wide association study identifies two new susceptibility loci for atopic dermatitis in the Chinese Han population. Nat Genet 2011;43:690-4.
77. Ahn K. The role of air pollutants in atopic dermatitis. J Allergy Clin Immunol 2014;134:993-1000.
78. Sargen MR, Hoffstad O, Margolis DJ. Warm, humid, and high sun exposure climates are associated with poorly controlled eczema: PEER (Pediatric Eczema Elective Registry) cohort, 2004-2012. J Invest Dermatol 2014;134:51-7.
79. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012;486:207-14.
80. Grice EA, Segre JA. The skin microbiome. Nat Rev Microbiol 2011;9:244-53.